ArticlePloS one2026
An immunoinformatics-driven multiepitope subunit vaccine targeting Oropouche virus: Molecular docking, immune and dynamics simulation approaches.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Oropouche virus (OROV) is an emerging zoonotic orthobunyavirus responsible for recurring outbreaks of febrile illness and neurological disorders in South and Central America. Despite its growing public health issues, no FDA-approved vaccines or antiviral therapies currently exist. To address this gap, a multiepitope subunit vaccine was designed to target OROV glycoproteins G1 (Gn), G2 (Gc), and the nucleocapsid (N) protein using a reverse-vaccinology (RV) approach. For vaccine construction, suitable epitopes (MHC-I, MHC-II, and linear B-cell) were selected based on percentile rank, antigenicity, allergenicity, and toxicity. However, the biophysical attributes demonstrated advantageous characteristics, including stability and solubility (GRAVY score: -0.432). The structural modelling exhibited a Ramachandran and Z scores of 91.86% (most favoured regions) and -1.81, respectively. However, the molecular docking with TLR-2 and TLR-4 receptors showed probable interactions (-1126.8 kJ/mol) and (-1239.4 kJ/mol), respectively. Moreover, dynamics simulation of the vaccine and Vaccine-TLR-4 complexes confirmed probable dynamic stability and compactness. The codon optimisation for Escherichia coli K12 expression yielded a CAI value of 1.0 and a GC content of (30-70) %, indicating optimal expression. The immune simulation predicted strong antibody-mediated and T cell-mediated immunity, including elevated IFN-γ, IgG, and memory cell populations. These findings suggest the potential of multiepitope subunit vaccines as a promising preventive candidate against OROV. However, additional experimental verification is required to confirm its immunogenicity and safety in experimental settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.